Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties

European Journal of Medicinal Chemistry

Volumn 38, Issue 4, 2003, Pages 397-402

  Drabczyńska, Anna ^a   Schumacher, Britta ^b   Müller, Christa E ^b   Karolak Wojciechowska, Janina ^c   Michalak, Barbara ^a   Pȩkala, Elzbieta ^a   Kieć Kononowicz, Katarzyna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF BONN   (Germany)

^c LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Adenosine A2A receptors antagonists; Adenosine receptors antagonists; Annelated xanthines; Pyrimido 2,1 f xanthines

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

CONFERENCE PAPER; DRUG ANTAGONISM; DRUG IDENTIFICATION; DRUG SELECTIVITY; DRUG STRUCTURE;

EID: 0037717165     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(03)00051-5     Document Type: Conference Paper

References (46)

1. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, K.-N. Klotz, J. Linden, Pharmacol. Rev., International Union of Pharmacology XXV Nomenclature and Classification of Adenosine Receptors 53 (2001) 527-552.
2. Ribeiro J.A., Cunha-Reis D., Lopes L.V., Coelho J.E., Costenla A.R., Correia-de-Sá P., Cunha R.A., de Mendonça A., Sebastião A.M. Drug Dev. Res. 52:2001;337-345.
3. Ciruela F., Escriche M., Soloviev M.M., Canela E.I., Burgeño J., Mallol J., Chan W.-Y., Lluis C., McIlhinney R.A.J., Franco R. Drug Dev. Res. 52:2001;316-322.
4. Ribeiro J.A. Eur. J. Pharmacol. 375:1999;101-113.
5. Kaiser S.M., Quinn R.J. Drug Discov. Today. 4:1999;542-551.
6. Poulsen S.-A., Quinn R.J. Bioorg. Med. Chem. 6:1998;619-641.
7. DeNinno M.P. Annu. Rep. Med. Chem. 33:1998;111-120.
8. Dickenson A.H., Suzuki R., Reeve A.J. CNS Drugs. 13:2000;77-85.
9. Shneyvays V., Safran N., Halili-Rutman I., Shainberg A. Drug Dev. Res. 50:2000;324-337.
10. Kourounakis A.P., Van der Klein P.A.M., IJzerman A.P. Drug Dev. Res. 49:2000;227-237.
11. Müller C.E., Stein B. Curr. Pharm. Des. 2:1996;501-530.
12. Hess S. Expert Opin. Ther. Patents. 11:2001;1533-1561.
13. Klotz K.-N., Hessling J., Owman C., Kull B., Fredholm B.B., Lohse M.J. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;1-9.
14. Klotz K.-N. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;382-391.
15. Müller C.E. Curr. Med. Chem. 7:2000;1269-1288.
16. Bruns R.F., Fergus J.H. J. Pharm. Pharmacol. 41:1989;590-594.
17. Shryock J.C., Ozeck M.J., Belardinelli L. Mol. Pharmacol. 53:1998;886-893.
18. El Yacoubi M., Ledent C., Parmentier M., Costentin J., Vaugeois J.-M. Eur. J. Pharmacol. 401:2000;63-77.
19. Chordia M.D., Murphree L.J., Macdonald T.L., Linden J., Olsson R.A. Bioorg. Med. Chem. Lett. 12:2002;1563-1566.
20. Baraldi P.G., Zaid A.N., Lampronti I., Fruttarolo F., Pavani M.G., Tabrizi M.A., Shryock J.C., Leung E., Romagnoli R. Bioorg. Med. Chem. Lett. 10:2000;1953-1957.
21. Müller C.E. Il Farmaco. 56:2001;77-80.
22. Ongini E., Monopoli A., Cacciari B., Baraldi P.G. Il Farmaco. 56:2001;87-90.
23. Sauer R., Maurinsh J., Reith U., Fülle F., Klotz K.-N., Müller C.E. J. Med. Chem. 43:2000;440-448.
24. Jacobson K.A., IJzerman A.P., Linden J.M. Drug Dev. Res. 47:1999;45-53.
25. Linden J.M., US6117878 (2000).
26. Kim Y.-C., Ji X.-D., Melman N., Linden J., Jacobson K.A. J. Med. Chem. 43:2000;1165-1172.
27. Hayallah A.M., Sandoval-Ramirez J., Reith U., Schobert U., Preiss B., Schumacher B., Daly J.W., Müller C.E. J. Med. Chem. 45:2002;1500-1510.
28. Salvatore C.A., Jacobson M.A., Taylor H.E., Linden J., Johnson R.G. Proc. Natl. Acad. Sci. USA. 90:1993;10365-10369.
29. Kim Y.-C., Karton Y., Ji X.-D., Melman N., Linden J., Jacobson K.A. Drug Dev. Res. 47:1999;178-188.
30. Boehringer Ingelheim: WO9803511 (1998).
31. Boehringer Ingelheim Pharm: EP0978517 (2000).
32. Boehringer Ingelheim Pharm: WO9965912 (1999).
33. Boehringer Ingelheim Pharm: WO0012511 (2000).
34. Weyler S., Müller C.E. Arch. Pharm. Pharm. Med. Chem. 334:(Suppl. 2):2001;C80 52.
35. Suzuki F., Shimada J., Nonake H., Ishii A., Shiozaki S., Ichikawa S., Ono E. J. Med. Chem. 35:1992;3578-3581.
36. Müller C.E., Thorand M., Qurishi R., Diekmann M., Jacobson K.A., Padgett W.L., Daly J.W. J. Med. Chem. 45:2002;3440-3450.
37. Müller C.E., Diekmann M., Thorand M., Ozola V. Bioorg. Med. Chem. Lett. 12:2002;501-503.
38. Baraldi P.G., Nasser A.Z., Fruttarolo F., Tabrizi M.A., Nunez M.del.C, Spalluto G., Romagnoli R. Synthesis. 2001;773-775.
39. Rockitt S., Duddeck H., Drabczyńska A., Kieć-Kononowicz K. Eur. J. Org. Chem. 2000;3489-3496.
40. Rockitt S., Wartchow R., Duddeck H., Drabczyńska A., Kieć-Kononowicz K. Z. Naturforsch. 56b:2001;319-324.
41. Kieć-Kononowicz K., Drabczyńska A., Pȩkala E., Michalak B., Müller C.E., Schumacher B., Karolak-Wojciechowska J., Duddeck H., Rockitt S., Wartchow R. Pure Appl. Chem. 73:2001;1411-1420.
42. Bogdał D. Wiadomości Chemiczne. 53:1999;66-99.
43. Bogdał D., Pielichowski J., Jaskot K. Org. Prep. Proc. Int. 30:1998;427-432.
44. Gao Z.-G., IJzerman A.P. Biochem. Pharmacol. 60:2000;669-676.
45. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., Swinyard E.A. Epilepsia. 19:1978;400-428.
46. Porter R.A., Cereghino J.J., Gladding G.D., Kupferberg H.J., Scoville B., White B.G. Cleveland Clin. Q. 51:1984;293-305.